BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35548379)

  • 41. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells.
    Scheeren LE; Nogueira-Librelotto DR; Mathes D; Pillat MM; Macedo LB; Mitjans M; Vinardell MP; Rolim CMB
    Toxicol In Vitro; 2021 Sep; 75():105192. PubMed ID: 33984456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy.
    Jiang W; Chen L; Guo X; Cheng C; Luo Y; Wang J; Wang J; Liu Y; Cao Y; Li P; Wang Z; Ran H; Zhou Z; Ren J
    Theranostics; 2022; 12(6):2987-3006. PubMed ID: 35401832
    [No Abstract]   [Full Text] [Related]  

  • 44. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
    Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
    J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters.
    Li K; Lai H
    Biomed Pharmacother; 2017 Dec; 96():371-377. PubMed ID: 29028589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
    Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
    Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening Multidrug Resistance Reversal Agents in Traditional Chinese Medicines by Efflux Kinetics of D-Luciferin in MCF-7/DOX
    Zhao Y; Tang C; Huang J; Zhang H; Shi J; Xu S; Ma L; Peng C; Liu Q; Xiong Y
    ACS Omega; 2023 Feb; 8(5):4853-4861. PubMed ID: 36777569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesoporous platinum nanoparticle-based nanoplatforms for combined chemo-photothermal breast cancer therapy.
    Fu B; Dang M; Tao J; Li Y; Tang Y
    J Colloid Interface Sci; 2020 Jun; 570():197-204. PubMed ID: 32151829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Folate-Targeted Redox-Responsive Polymersomes Loaded with Chemotherapeutic Drugs and Tariquidar to Overcome Drug Resistance.
    Qin Y; Zhang Z; Huang C; Fan F; Liu L; Lu L; Wang H; Liu Z; Yang J; Wang C; Yang H; Sun H; Leng X; Kong D; Zhang L; Zhu D
    J Biomed Nanotechnol; 2018 Oct; 14(10):1705-1718. PubMed ID: 30041718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
    Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
    ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
    Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
    Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
    Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
    Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The enhanced chemotherapeutic effects of doxorubicin loaded PEG coated TiO
    Du Y; Ren W; Li Y; Zhang Q; Zeng L; Chi C; Wu A; Tian J
    J Mater Chem B; 2015 Feb; 3(8):1518-1528. PubMed ID: 32262424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Study on mechanism of elemene reversing tumor multidrug resistance based on luminescence pharmacokinetics in tumor cells
    Chen L; Chen Z; Zheng S; Fan L; Zhu L; Yu J; Tang C; Liu Q; Xiong Y
    RSC Adv; 2020 Sep; 10(57):34928-34937. PubMed ID: 35514396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.
    Yu H; Li JM; Deng K; Zhou W; Wang CX; Wang Q; Li KH; Zhao HY; Huang SW
    Theranostics; 2019; 9(23):7033-7050. PubMed ID: 31660085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biodegradable PEG-PCL Nanoparticles for Co-delivery of MUC1 Inhibitor and Doxorubicin for the Confinement of Triple-Negative Breast Cancer.
    Behl A; Solanki S; Paswan SK; Datta TK; Saini AK; Saini RV; Parmar VS; Thakur VK; Malhotra S; Chhillar AK
    J Polym Environ; 2023; 31(3):999-1018. PubMed ID: 36405816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.